Targeted antitumour therapy – future perspectives

Perspectives HER-2-Targeted Therapy: Lessons Learned and Future Directions

HER-2 is overexpressed in 20–25% of invasive breast cancers and is associated with an aggressive tumor phenotype and reduced survival rates. The HER-2 status of a tumor is the critical determinant of response to the HER-2targeted antibody trastuzumab. Thus, accurate assessment of HER-2 expression levels is essential for identifying breast cancer patients who will benefit from HER-2-targeted the...

Membrane Engineering: Future Perspectives

Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives

Despite the survival of pediatric patients affected by hematological malignancies being improved in the last 20 years by chemotherapy and hematopoietic stem cell transplantation, a significant amount of patients still relapses. Treatment intensification is limited by toxic side effects and is constrained by the plateau of efficacy, while the pipeline of new chemotherapeutic drugs is running sho...

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.

Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%-75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, novel precise OS-targeting therapies are being developed with the hope of addressing this issue. T...

Cancer Gene Therapy - Developments and Future Perspectives

David A Good1,2, Wei Duan3, Jozef Anné4 and Ming Q Wei1 1Division of Molecular Medicine and Gene Therapy, Griffith Health Institute, Schoolof Medical Science, Gold Coast campus, Griffith University, Qld, 2School of Physiotherapy, Australian Catholic University, McAuley Campus, Banyo, Qld, 3School of Medicine, Deakin University, Waurn Ponds, VIC., 4Rega Institute for Medical Research, Minderbroe...